MedTrace Logo

Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin

NCT02212795 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-06-29

No results posted yet for this study

Summary

Phase I clinical study to compare the pharmacokinetic profiles and bactericidal activity of Zabofloxacin 183mg, 367mg and Levofloxacin 250mg after oral administration in healthy volunteer

Conditions

  • Healthy

Interventions

DRUG

Zabofloxacin 183mg

Zabofloxacin 183mg single dose

DRUG

Levofloxacin 250mg

Levofloxacin 250mg single dose

DRUG

Zabofloxacin 367mg

Zabofloxacin 367mg single dose

Sponsors & Collaborators

  • Dong Wha Pharmaceutical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • MinGul Kim, M.D · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-08-31
Completion
2014-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02212795 on ClinicalTrials.gov